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Abstract
Background: It has been proposed that cyclin G1 (CCNG1) participates in p53-dependent G1–S and G2 checkpoints
and might function as an oncogenic protein in the initiation and metastasis of ovarian carcinoma. MicroRNA 23b
(miR-23b) is a critical regulatory factor in the progression of many cancer cell types that targets the relevant genes.
Methods: MiR-23b expression in ovarian tissues was quantified by quantitative reverse transcription–PCR. The
ovarian cancer cell lines OVCAR3, HO8910-PM, and SKOV3/DDP were transfected with miR-23b, after we assayed the
cell phenotype and expression of the relevant molecules. Dual-luciferase reporter assay and a xenograft mouse
model were used to examine the expression of miR-23b and its target gene CCNG1.
Results: MIR23B mRNA expression was significantly lower in epithelial ovarian carcinoma and borderline tumors
than in normal ovarian tissues and benign tumors, and miR-23b expression among ages and pathological subtypes
was significantly different. CCNG1 mRNA expression was significantly lower in normal ovarian tissues than in benign
tumors, borderline tumors, and ovarian carcinomas, and expression among pathological subtypes was significantly
different. MiR-23b overexpression inhibited ovarian cancer cell proliferation, invasion, and migration, and induced
apoptosis. Dual-luciferase reporter assay showed that miR-23b bound with the 3′ untranslated region of CCNG1.
MiR-23b overexpression significantly downregulated CCNG1, urokinase, survivin, Bcl-xL, P70S6K, and matrix
metallopeptidase-9 (MMP9) mRNA and protein expression. Furthermore, miR-23b inhibited tumor growth and
suppressed CCNG1 expression in vitro.
Conclusions: Our findings show that miR-23b may inhibit ovarian cancer tumorigenesis and progression by
downregulating CCNG1 and the expression of the relevant genes. MiR-23b is a potentially novel application for
regulating ovarian carcinoma progression.
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Background
The incidence of ovarian cancer is perpetually high:
200,000 new cases are diagnosed annually worldwide.
Each year, it constitutes 4 % of all cancers diagnosed in
women, and there are 6.6 new cases per 100,000 women
per year [1, 2]. Globally, ovarian cancer caused 160,500
deaths in 2010, an increase from the 113,600 in 1990 and
the 140,200 in 2008 [3, 4]. It also remains the most lethal
gynecologic malignancy owing to late detection, intrinsic
and acquired chemoresistance, and remarkable heterogen-
eity [5]; recurrence is frequently observed in up to 70 % of
cases [6]. In such patients, invasion, metastasis, and che-
moresistance may play important roles. Consequently, in-
creasingly sophisticated experiments have been performed
to study targeted treatments to improve the 5-year sur-
vival rate of patients with ovarian cancer.
MicroRNAs (miRNAs) are a class of small non-coding
RNAs that negatively regulate gene expression at post-
transcriptional level [7]. It has been demonstrated that a
small number of miRNAs actively participate in regulat-
ing tumor development; it has been shown that they play
different roles in different organs, particularly relating to
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cancer development [8–12]. It has been determined that
miR-23b mediates the various steps in the metastatic
process, including tumor growth, invasion, and even
angiogenesis by repressing a cohort of prometastatic tar-
gets [13]. MiR-23b is downregulated in many cancers
and acts as a tumor suppressor [14–16]. From a clinical
viewpoint, miR-23b has great potential as a diagnostic
and therapeutic agent in some tumors. Our previous
study showed that miR-23b was highly expressed in nor-
mal ovarian tissues than ovarian carcinoma tissues, and
our predicted seed region in the 3′ untranslated regions
(3′ UTR) of CCNG1 revealed that it’s a target of miR-
23b, thus we investigated the involvement of CCNG1
and miR-23b in ovarian cancer for the first time.
Methods
Cell culture
The ovarian cancer cell lines OVCAR3 and HO8910-PM
(highly invasive HO8910) were from ATCC. The
cisplatin-resistant SKOV3 (SKOV3/DDP) cell line was
purchased from the Tumor Cell Bank of the Chinese
Academy of Medical Science (Peking, China). The cells
were maintained in RPMI 1640 medium supplemented
with 10 % fetal bovine serum (FBS), 100 units/mL peni-
cillin and 100 μg/mL streptomycin in a humidified at-
mosphere of 5 % CO2 at 37 °C.
Proliferation assay
We used 3-(4,5)-dimethylthiazol (−zyl)-3,5-diphenyltetra-
zolium bromide (MTT; China) to determine the number
of viable cells. Briefly, approximately 2.5 × 103 cells/well
were seeded in a 96-well plate and allowed to adhere. At
different time points, 20 μL MTT solution was added to
each well, and the plates were incubated for 4 h. Subse-
quently, the MTT solution was removed, and 150 μL di-
methyl sulfoxide was added and incubated for 10 min
before the absorbance was measured at 490 nm.
Cell cycle analysis
After 48-h incubation, the cells were washed, collected,
and fixed in 10 mL ice-cold ethanol (70 %) for 12 h.
Then, the cells were washed, incubated with 5 μL RNase
(0.25 mg/mL) at 37 °C for 30 min, pelleted, resuspended
in 50 μg/mL PI, and incubated for 15 min in the dark at
room temperature. Cell cycle analysis was performed by
flow cytometric analysis.
Apoptosis assay
Flow cytometry was performed following PI and FITC-
labeled annexin V (KeyGen Biotech, Nanjing, China)
staining according to the manufacturer’s protocol. Briefly,
after 48-h incubation, cells were washed and resuspended
in 200 μL 1× binding buffer at 1 × 106 cells/mL, and incu-
bated with 5 μL FITC–annexin V; after 15-min incubation
at room temperature in the dark, 300 μL 1× binding
buffer together with 5 μL PI were added to each tube.
The samples were incubated for 30 min at room
temperature in the dark. Flow cytometry was per-
formed within 1 h.
Wound healing assay
Cells were seeded at 1 × 106 cells/well in 6-well cul-
ture plates. After they had grown to confluence, the
monolayer was scratched with a pipette tip (200 μL).
The cells were washed with PBS three times and cul-
tured in FBS-free medium, and then photographed at
0, 24, and 48 h. The scratched areas were measured
using ImageJ software, after which the wound healing
rate was calculated.
Cell invasion assay
5 × 104 cells were resuspended in FBS-free medium and
seeded into the top chambers of Matrigel™-coated
Transwell® inserts (BD Bioscience, San Jose, CA, USA).
The lower compartments of the chambers contained
10 % v/v FBS as a chemoattractant. After 48-h incuba-
tion, the cells on the upper surface of the membrane
were wiped away, and the cells on the lower surface of
the membrane were washed, fixed, and stained with
crystal violet to quantify the extent of invasion.
Ovarian carcinoma specimens
Specimens from 50 ovarian epithelial carcinomas, 13 be-
nign tumors, 5 borderline tumors, and 6 normal ovarian
tissues were collected from patients who underwent sur-
gical resection at the Department of Gynecology of the
First Affiliated Hospital of China Medical University
(Shenyang, China). Two pathologists confirmed the tumor
specimens independently. The China Medical University
Ethics Committee approved the study.
Real-time RT-PCR (real-time RT-PCR)
Real-time RT-PCR was performed from 2 μg total RNA
using AMV reverse transcriptase and random primers
(Takara). The PCR primers were designed according to
the GenBank sequences. The glyceraldehyde-3-phosphate
dehydrogenase gene (GAPDH) was used as the internal
control. The relative gene expression level (the amount of
target gene normalized to the endogenous control gene)
was calculated using the comparative threshold cycle
method: 2-ΔΔCt. Hairpin-it™ microRNA and U6 snRNA
Normalization RT-PCR Quantitation (GenePharma) were
used to examine mature miR-23b.
Western blotting
Proteins were separated by SDS-PAGE, transferred to
polyvinylidene difluoride membranes and immunoblotted
overnight at 4 °C with the primary antibodies (1:500),
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rinsed with TBST, and incubated with 1:5000 secondary
antibodies conjugated to horseradish peroxidase (Dako).
After applying electrochemiluminescence (ECL) Plus
detection reagents (Santa Cruz Biotechnology), pro-
tein bands were visualized using X-ray film (Fujifilm,
Tokyo, Japan). GAPDH-specific monoclonal antibody
(1:2000; Santa Cruz Biotechnology) was used as the
internal control.
In vivo nude mouse tumorigenicity assay
The assay was performed to determine the effects of miR-
23b overexpression on the tumorigenicity of OVCAR3
cells in vivo. Mock or hsa-miR-23b–transfected OVCAR3
cells (1 × 107) were injected subcutaneously into the flanks
of 4-6-week-old male nude mice (n = 5). Once tumor
growth had been established in the mock-treated mice
(14 days post-injection), tumor sizes were measured every
other day. Tumor volume (mean ± standard deviation)
was calculated as length × width2/2.
Immunofluorescence (IF) staining
5-μm frozen section from each sample was fixed in acet-
one at 4 °C overnight. After washing, sections were
blocked with 1 % bovine serum albumin for 30 min and
incubated overnight at 4 °C with rabbit anti-human
CCNG1 antibody (1:50). Then sections were incubated
with anti-rabbit IgG–FITC (1:100, Santa Cruz Biotech-
nology) for 2 h at room temperature in the dark. Nuclei
were stained with diaminophenylindole (1 μg/mL;
Sigma-Aldrich) for 5 min at room temperature. Cover-
slips were mounted and imaged using a laser confocal
microscope (Olympus, Tokyo, Japan).
Dual-luciferase reporter assay
A293 cells were first seeded at 60–80 % confluence in
24-well plates for 12 h. For the dual-luciferase reporter
assays, cells were transiently transfected with Wt or mu-
tated reporter plasmid and miR-23b or control-miR.
Firefly luciferase activity was measured using a Dual-
Luciferase Assay (Promega) 48 h after transfection, and
the results were normalized with Renilla luciferase. Each
reporter plasmid was transfected at least three times,
and each sample was assayed in triplicate.
Statistical analysis
Statistical evaluation was performed using Spearman’s
rank correlation coefficient to analyze ranked data; the
Mann–Whitney U test was used to differentiate the
means of different groups. A p-value of < 0.05 was con-
sidered statistically significant. SPSS v. 17.0 (SPSS) was
used to analyze all data.
Results
Correlation of MIR23B and cyclin G1 (CCNG1) mRNA
expression with pathogenesis and aggressiveness of
ovarian carcinoma
We quantified MIR23B and CCNG1 mRNA expression in
normal ovary tissue, benign and borderline tumors, and
primary ovarian carcinoma using real-time PCR. MIR23B
mRNA expression was significantly lower in the ovarian
carcinomas and borderline tumors than in the normal
ovarian tissues and benign tumors (Fig. 1a, p < 0.05), and
there were significant differences in expression among
ages (Fig. 1b, p < 0.05) and pathological subtypes (mucin-
ous vs. other types, Fig. 1d, p < 0.05). However, there were
no significant differences among International Federation
of Gynecology and Obstetrics (FIGO) stages (I/II vs. III/
IV, Fig. 1c, p > 0.05) and differentiation (well vs. poor and
moderate, data not shown, p > 0.05) in ovarian carcinoma.
CCNG1 mRNA expression was significantly lower in the
normal ovarian tissues and benign ovarian tumors than in
the ovarian carcinomas (Fig. 1e, p < 0.05).
Effects of miR-23b transfection on ovarian carcinoma cell
phenotype in vitro
We transfected OVCAR3, HO8910-PM, SKOV3/DDP
cells with miR-23b. The transfected cells exhibited
significantly slower growth (Fig. 2a, p < 0.05) but
higher levels of mature miR-23b expression than the
control and mock-transfected cells (Fig. 2b, p < 0.05).
MiR-23b overexpression significant induced G1 arrest
(Fig. 3a, p < 0.05), higher levels of apoptosis (Fig. 3b,
p < 0.05) and reduced cell migration (Fig. 4a, p < 0.05)
and invasion (Fig. 4b, p < 0.05) compared to the con-
trol and mock-transfected cells.
Effects of miR-23b transfection on ovarian carcinoma cell
genotype in vitro
The predicted seed region in the 3′ untranslated regions
(3′ UTR) of CCNG1 revealed that it is direct target
of miR-23b (Fig. 5a); dual-luciferase reporter assay
indicated that miR-23b significantly decreased the
relative luciferase activity of the wild-type CCNG1 3′
UTR as compared with the mutant CCNG1 3′ UTR,
indicating that miR-23b may directly bind to the 3′
UTR of CCNG1 (Fig. 5b). Reverse transcription
(RT)-PCR (Fig. 5c, p < 0.05) and western blotting
(Fig. 5d) showed that miR-23b overexpression reduced
CCNG1, urokinase (uPA), P70S6K, Bcl-xL, survivin, and
matrix metallopeptidase 9 (MMP9) mRNA or protein
expression.
MiR-23b inhibited tumor growth in vivo
The tumor xenograft volume in nude mice treated with
miR-23b was smaller than that in the mock-treated mice
(Fig. 6a, p < 0.05). From day 4 and week 2 onwards, the
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tumor xenograft growth in the miR-23b–treated BALB/c
mice was slower than that in the mock group (Fig. 6b,
pday 4 < 0.05; pdeviation of tumor xenograft volume [DV] < 0.01,
and pweek 2 < 0.05; pDV < 0.01), and the DV increased in
the latter period.
MiR-23b downregulated CCNG1 expression in tumor
xenografts in vivo
Immunofluorescence staining (IF) indicated decreased
CCNG1 expression in the tumor xenografts of the miR-
23b–treated nude mice compared with that in the
mock-treated nude mice (Fig. 7).
Discussion
MiRNAs regulate their target genes by affecting base
pairing to their 3′ UTRs, resulting in mRNA degrad-
ation or inhibition of translation [11]. An increasing
number of studies have revealed that miRNAs are prom-
ising diagnostic and prognostic molecular biomarkers as
well as therapeutic targets in cancer [17, 18]. Series of
studies has reported that miR-23b acts as a tumor sup-
pressor in different cancers [19]. Majid et al. showed that
miR-23b has diagnostic/prognostic significance and dir-
ectly targets the oncogenic ZEB1 in bladder cancer [14].
He et al. reported that miR-23b expression levels in pros-
tate carcinoma (PCa) tissues was significantly correlated
Fig. 1 Correlation of MIR23B and CCNG1 mRNA expression with pathogenesis and aggressiveness of ovarian carcinoma. a MIR23B mRNA
expression was significantly lower in the ovarian carcinomas and borderline ovarian tumors than in the normal ovarian tissues and benign
tumors; b there were significant differences in expression among age and d pathological subtype (mucinous vs. other types) in the ovarian
carcinoma tissues. c There were no significant differences among FIGO stage (I/II vs. III/IV) in ovarian carcinoma. e CCNG1 mRNA expression was
significantly lower in the normal ovarian tissues and benign ovarian tumors than in the ovarian carcinomas. *p < 0.05 vs. normal ovarian tissues;
#p < 0.05 vs. benign ovarian tumors. No = Normal ovarian tissues, Be = benign ovarian tumors, Bo = borderline ovarian tumors, Om = omentum
tumors, Mu =mucinous carcinoma, Ser = serous carcinoma
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Fig. 2 Effects of miR-23b transfection on ovarian carcinoma cell proliferation in vitro. a Following miR-23b transfection, OVCAR3, HO8910-PM,
SKOV3/DDP cell lines exhibited significantly slower growth and b higher levels of mature miR-23b expression than the control and mock-
transfected cells. Results are representative of three separate experiments; data are expressed as the mean ± standard deviation, * p < 0.05
Fig. 3 Effects of miR-23b transfection on ovarian carcinoma cell cycle and apoptosis in vitro. MiR-23b transfection induced a G1 arrest and b early
apoptosis in OVCAR3, HO8910-PM, and SKOV3/DDP cells as compared to the control and mock-transfected cells. Results are representative of
three separate experiments; data are expressed as the mean ± standard deviation, * p < 0.05
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with that of peroxiredoxin 3 (PRDX3) and that miR-23b
may be involved in the response of PCa cells to hypoxic
stress, therefore gene therapy using miRNA mimics may
be useful as PCa therapy [20]. Our results show that
MIR23B mRNA expression was significantly lower in
ovarian carcinomas and borderline tumors than in normal
ovarian tissues and benign tumors, and the expression
among age and pathological subtypes (mucinous vs. other
types) was significantly different. These findings indicate
that miR-23b might affect ovarian epithelial carcinogen-
esis and the subsequent progression. Therefore, we ex-
plored the function and molecular mechanism of miR-23b
in ovarian cancer cell lines.
Ovarian cancer cells transfected with miR-23b had sig-
nificantly slower growth than the negative control– and
mock-transfected cells, and there was significantly in-
duced G1 arrest and apoptosis and reduced cell invasion
and migration, suggesting miR-23b may inhibit ovarian
carcinoma tumorigenesis and progression. Moreover, the
predicted seed region showed that miR-23b targets
CCNG1 3′ UTR, which was convinced by the dual-
luciferase reporter assay. We also found that miR-23b
transfection decreased CCNG1 mRNA and protein ex-
pression. CCNG1 was first identified as a p53-regulated
transcript induced by DNA damage. It has been pro-
posed that these events underpin CCNG1 participation
in the enforcement of the p53-dependent G1–S and G2
checkpoints responsive to DNA damage [21]. Some have
suggested that CCNG1 might function as an oncogenic
protein [22, 23] and play a pivotal role in the initiation
and metastasis of hepatocellular carcinoma [24]. Russell
et al. reported that CCNG1 amplification is associated
with significantly shorter postsurgical survival in pa-
tients with ovarian cancer who have received adjuvant
chemotherapy with taxanes and platinum compounds
[21]. These results suggest that miR-23b may inhibit
ovarian cancer tumorigenesis and progression by tar-
geting CCNG1.
Fig. 4 Effects of miR-23b transfection on the invasive and metastatic ability of ovarian carcinoma cell lines. After transfection with the miR-23b
mimic, ovarian carcinoma cells showed a lower migration and b slower invasion as compared with the control and mock-transfected cells. Results
are representative of three separate experiments; data are expressed as the mean ± standard deviation, *p < 0.05
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In this study, we also found that miR-23b overexpres-
sion downregulated uPA expression, which is in line
with the findings of Salvi et al. [15], who reported that
miR-23b overexpression leads to uPA downregulation
and decreased migration and proliferation ability in
hepatocellular carcinoma cells. Furthermore, miR-23b
overexpression also downregulated the expression of
P70S6K, survivin, Bcl-xL, and MMP9 mRNA and pro-
tein. It has been established that uPA is integral to cell
differentiation, migration, tissue remodeling under
physiological and pathological conditions, and may be a
potential diagnostic biomarker and therapeutic target in
cancer. Significant elevation of uPA protein levels in pri-
mary ovarian cancer tissue has been associated with
poor prognosis and disease progression [25–29]. The
uPA system plays an important role in many patho-
physiological processes, such as cell differentiation, mi-
gration, tissue reconstruction, and matrix dissolution
[30]. The aberrant expression of phosphorylated P70S6K
might contribute to the pathogenesis, growth, invasion,
and metastasis of cancer [31]. Wang et al. reported that
uPA promoted carcinoma cell proliferation by stimulat-
ing P70S6K activation [32]. Survivin, a member of the
inhibitors of apoptosis protein family, is expressed dur-
ing development and in various human cancers. Lee et
al. reported that downregulating survivin suppressed
uPA through the transcription factor JunB [33]. Ryan et
al. reported that survivin expression in breast cancer
predicts clinical outcome and is associated with uPA
[34]. Furthermore, Zhou et al. reported that Bcl-xL over-
expression strongly enhanced uPA in pancreatic ductal
adenocarcinoma cells [35]. Therefore, we suggest that
miR-23b reduces cell proliferation by downregulating
CCNG1 and uPA/P70S6K expression, suppresses cell
migration and invasion by downregulating uPA/MMP9
expression, and induces apoptosis by downregulating
survivin and Bcl-xL/uPA expression.
We found that CCNG1 mRNA expression was signifi-
cantly lower in the normal ovarian tissues and benign
ovarian tumors than in the borderline ovarian tumors
Fig. 5 Effects of miR-23b transfection on ovarian carcinoma cell genotype in vitro. a The predicted seed region in the 3′ UTR of CCNG1 revealed
that CCNG1 was direct target of miR-23b, as predicted by microRNA.org; b dual-luciferase reporter assay indicated that miR-23b significantly
decreased the relative luciferase activity of the wild-type CCNG1 3′ UTR as compared with the mutant CCNG1 3′ UTR, indicating that miR-23b
may directly bind to the 3′ UTR of CCNG1. c & d MiR-23b overexpression reduced CCNG1, uPA, P70S6K, Bcl-xL, survivin and MMP9 mRNA or
protein expression. * p < 0.05
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and ovarian carcinomas. Our subsequent in vivo
tumor xenograft studies showed that miR-23b inhib-
ited tumor growth and decreased CCNG1 expression.
Recent studies have reported that CCNG1 gene ther-
apy has been developed and has undergone phase I/II
clinical trials for treating colorectal and pancreatic
cancer [36]. We suggest that miR-23b may also be a
potential suppressor of ovarian carcinoma by targeting
CCNG1.
Our findings show that miR-23b may inhibit ovarian
cancer tumorigenesis and progression by downregulating
CCNG1 and the expression of the relevant genes, and
that miR-23b is a potentially novel application for regu-
lating ovarian carcinoma progression.
Fig. 6 MiR-23b inhibited tumor growth in vivo. a Tumor xenograft volume in nude mice treated with hsa-miR-23b was smaller than that in mock-
treated mice. b Tumor xenograft growth in miR-23b–treated nude mice was slower than that in the mock group from day 4 and week 2 onwards
Fig. 7 MiR-23b downregulated CCNG1 expression in tumor xenografts in vivo. IF experiments indicated that CCNG1 expression in the tumor
xenografts of miR-23b–treated nude mice were decreased compared with that in the mock-treated nude mice
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Conclusion
This is the first demonstration that miR-23b may inhibit
EOC tumorigenesis and progression by targeting CCNG1
and modulating the expression of the relevant genes.
These findings indicate that miR-23b is a potential
suppressor of ovarian carcinoma tumorigenesis and pro-
gression. The involvement of miR-23b–mediated CCNG1
downregulation in inhibiting EOC aggressiveness may
yield further insight into the molecular mechanisms
underlying cancer aggressiveness.
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